Reuters logo
BRIEF-Arbutus to Receive $116 Million Strategic Investment from Roivant Sciences
October 2, 2017 / 11:23 AM / 3 months ago

BRIEF-Arbutus to Receive $116 Million Strategic Investment from Roivant Sciences

Oct 2 (Reuters) - Arbutus Biopharma Corp:

* Signed share purchase agreement with Roivant Sciences for sale of convertible preferred shares for $116.4 million

* Intends to use proceeds from sale to further develop, advance its clinical, preclinical HBV pipeline programs

* Roivant will invest preferred shares which will be convertible into common shares at conversion price of $7.13/share

* Roivant has agreed to a four year lock‐up period for the preferred shares investment and its existing holdings in co Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below